Current Oral Health Reports

, Volume 3, Issue 2, pp 102–110 | Cite as

Molecular Markers of Fibro-Osseous Lesions and Osteosarcomas of the Craniofacial Complex—Current Situation and Recent Advances

  • Flore Tabareau-Delalande
  • Gonzague de PinieuxEmail author
Oral Neoplasia (F Alawi and A Le, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Oral Neoplasia


Fibro-osseous lesions share clinical, radiological, and pathological features, particularly in the craniofacial complex, a location where diagnosing these lesions is challenging. Some molecular markers involved in the pathogenesis of these lesions offer significant diagnostic support. Guanine nucleotide-binding protein/alpha subunit (GNAS) mutations are specific to fibrous dysplasias and are not encountered in ossifying fibromas (including juvenile variants), or in low-grade and high-grade osteosarcomas of the jaw. Low-grade and dedifferentiated osteosarcomas show murine double-minute 2 (MDM2) amplification, with overexpression of MDM2, abnormalities not encountered in fibrous dysplasia, or in ossifying fibroma. No recurrent cytogenetic or molecular abnormality has been reported to date in conventional ossifying fibromas. The juvenile variants of ossifying fibroma exhibit MDM2/RAS protein activator like-1 (RASAL1) co-amplification, without MDM2 overexpression, abnormalities also observed in certain aggressive osteosarcomas of the jaw, which may derive from juvenile ossifying fibroma. MDM2/RASAL1 co-amplification may constitute an early molecular marker of aggressive juvenile ossifying fibroma and may indicate a need for closer follow-up and more radical treatment.


Fibro-osseous lesions Craniofacial complex Fibrous dysplasia Ossifying fibroma Juvenile ossifying fibroma Low-grade osteosarcoma 


Compliance with Ethical Standards

Conflict of Interest

Flore Tabareau-Delalande and Gonzague de Pinieux declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Voytek TM, Ro JY, Edeiken J, et al. Fibrous dysplasia and cemento-ossifying fibroma. A histologic spectrum. Am J Surg Pathol. 1995;19(7):775–81.Google Scholar
  2. 2.
    Slootweg PJ. Maxillofacial fibro-osseous lesions: classification and differential diagnosis. Semin Diagn Pathol. 1996;13(2):104–12.Google Scholar
  3. 3.
    Franceschina MJ, Hankin RC, Irwin RB. Low-grade central osteosarcoma resembling fibrous dysplasia. A report of two cases. Am J Orthop. 1997;26(6):432–40.PubMedGoogle Scholar
  4. 4.
    Muramatsu K, Hashimoto T, Seto S, et al. Low-grade central osteosarcoma mimicking fibrous dysplasia: a report of two cases. Arch Orthop Trauma Surg. 2008;128(1):11–5.Google Scholar
  5. 5.
    Alawi F. Benign fibro-osseous diseases of the maxillofacial bones. A review and differential diagnosis. Am J Clin Pathol. 2002;118(Suppl):S50–70.PubMedGoogle Scholar
  6. 6.
    DiCaprio MR, Enneking WF. Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J Bone Joint Surg Am. 2005;87(8):1848–64.CrossRefPubMedGoogle Scholar
  7. 7.
    Toyosawa S, Yuki M, Kishino M, et al. Ossifying fibroma vs fibrous dysplasia of the jaw: molecular and immunological characterization. Mod Pathol. 2007;20(3):389–96.Google Scholar
  8. 8.
    Suarez-Soto A, Baquero-Ruiz de la Hermosa MC, Minguez-Martinez I, et al. Management of fibro-osseous lesions of the craniofacial area. Presentation of 19 cases and review of the literature. Med Oral Patol Oral Cir Bucal. 2013;18(3):e479–85.Google Scholar
  9. 9.
    Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688–95.Google Scholar
  10. 10.
    Shenker A, Weinstein LS, Sweet DE, et al. An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab. 1994;79(3):750–5.Google Scholar
  11. 11.
    Alman BA, Greel DA, Wolfe HJ. Activating mutations of Gs protein in monostotic fibrous lesions of bone. J Orthop Res. 1996;14(2):311–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Marie PJ, de Pollak C, Chanson P, et al, Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol. 1997;150(3):1059–69.Google Scholar
  13. 13.
    Sakamoto A, Oda Y, Iwamoto Y, et al. A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to expressions of c-fos and c-jun products and bone matrix proteins: a clinicopathologic review and immunohistochemical study of c-fos, c-jun, type I collagen, osteonectin, osteopontin, and osteocalcin. Hum Pathol. 1999;30(12):1418–26.Google Scholar
  14. 14.
    Happle R. The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet. 1986;29(4):321–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Bianco P, Kuznetsov SA, Riminucci M, et al. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. J Clin Invest. 1998;101(8):1737–44.Google Scholar
  16. 16.
    Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci U S A. 1992;89(11):5152–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Okamoto S, Hisaoka M, Ushijima M, et al. Activating Gs(alpha) mutation in intramuscular myxomas with and without fibrous dysplasia of bone. Virchows Arch. 2000;437(2):133–7.Google Scholar
  18. 18.
    Matsuzaka K, Shimono M, Uchiyama T, et al. Lesions related to the formation of bone, cartilage or cementum arising in the oral area: a statistical study and review of the literature. Bull Tokyo Dent Coll. 2002;43(3):173–80.Google Scholar
  19. 19.
    Flechter CDM, BJ, Hogendoorn P, Mertens F, World Health Organization, International Agency for Research on Cancer. Classification of tumours of soft tissue and bone. 5th ed. Lyon: IARC Press. 2013.Google Scholar
  20. 20.
    Posnick JC. Fibrous dysplasia of the craniomaxillofacial region: current clinical perspectives. Br J Oral Maxillofac Surg. 1998;36(4):264–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Waldron CA. Fibro-osseous lesions of the jaws. J Oral Maxillofac Surg. 1993;51(8):828–35.CrossRefPubMedGoogle Scholar
  22. 22.
    Lee JS, FitzGibbon EJ, Chen YR, et al. Clinical guidelines for the management of craniofacial fibrous dysplasia. Orphanet J Rare Dis. 2012;7 Suppl 1:S2.Google Scholar
  23. 23.
    Eversole R, Su L, ElMofty S. Benign fibro-osseous lesions of the craniofacial complex. Rev Head Neck Pathol. 2008;2(3):177–202.CrossRefGoogle Scholar
  24. 24.
    Tokano H, Sugimoto T, Noguchi Y, et al. Sequential computed tomography images demonstrating characteristic changes in fibrous dysplasia. J Laryngol Otol. 2001;115(9):757–9.Google Scholar
  25. 25.
    Brannon RB, Fowler CB. Benign fibro-osseous lesions: a review of current concepts. Adv Anat Pathol. 2001;8(3):126–43.CrossRefPubMedGoogle Scholar
  26. 26.
    Fletcher CD, Bridge JA, Hogendoorn P, et al. World Health Organization classification of tumours of soft tissue and bone. Lyon: IARC Press; 2013. p. 468.Google Scholar
  27. 27.•
    Tabareau-Delalande F, Collin C, Gomez-Brouchet A, et al. Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions. Mod Pathol. 2013;26:911–21. This manuscript represents the first large study indicating that mutational analysis of GNAS gene constitutes a valuable diagnostic tool in fibrous dysplasia in routine practice, in particular allowing to differentiate ossifying fibroma and fibrous dysplasia of the jaws.Google Scholar
  28. 28.
    Riminucci M, Liu B, Corsi A, et al. The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks. J Pathol. 1999;187(2):249–58.Google Scholar
  29. 29.
    Gorelov VN, Dumon K, Barteneva NS, et al. Overexpression of Gs alpha subunit in thyroid tumors bearing a mutated Gs alpha gene. J Cancer Res Clin Oncol. 1995;121(4):219–24.Google Scholar
  30. 30.
    Lietman SA, Ding C, Levine MA. A highly sensitive polymerase chain reaction method detects activating mutations of the GNAS gene in peripheral blood cells in McCune-Albright syndrome or isolated fibrous dysplasia. J Bone Joint Surg Am. 2005;87(11):2489–94.CrossRefPubMedGoogle Scholar
  31. 31.
    Riminucci M, Fisher LW, Majolagbe A, et al. A novel GNAS1 mutation, R201G, in McCune-albright syndrome. J Bone Miner Res. 1999;14(11):1987–9.Google Scholar
  32. 32.
    Idowu BD, Al-Adnani M, O’Donnell P, et al. A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone. Histopathology. 2007;50(6):691–704.Google Scholar
  33. 33.
    Lee SE, Lee EH, Park H, et al. The diagnostic utility of the GNAS mutation in patients with fibrous dysplasia: meta-analysis of 168 sporadic cases. Hum Pathol. 2012;43(8):1234–42Google Scholar
  34. 34.
    Shi RR, Li XF, Zhang R, et al. GNAS mutational analysis in differentiating fibrous dysplasia and ossifying fibroma of the jaw. Mod Pathol. 2013;26(8):1023–31.Google Scholar
  35. 35.
    Tabareau-Delalande F, Collin C, Larousserie F, et al. Comments on Carter et al.’s “activating GNAS mutations in parosteal osteosarcoma”. Am J Surg Pathol. 2015;39(7):1010–3.Google Scholar
  36. 36.
    Salinas-Souza C, De Andrea C, Bihl M, et al. GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. Mod Pathol. 2015;28(10):1336–42.Google Scholar
  37. 37.
    Jour G, Oultache A, Sadowska J, et al. GNAS mutations in fibrous dysplasia: a comparative study of standard sequencing and locked nucleic acid PCR sequencing on decalcified and nondecalcified formalin-fixed paraffin-embedded tissues. Appl Immunohistochem Mol Morphol, 2015.Google Scholar
  38. 38.
    Guérin M, Thariat J, Ouali M, et al. A new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification. Human Pathol. 2016;50:70–8.Google Scholar
  39. 39.
    Kuznetsov SA, Cherman N, Riminucci M, et al. Age-dependent demise of GNAS-mutated skeletal stem cells and “normalization” of fibrous dysplasia of bone. J Bone Miner Res. 2008;23(11):1731–40.Google Scholar
  40. 40.
    Liang Q, Wei M, Hodge L, et al. Quantitative analysis of activating alpha subunit of the G protein (Gsalpha) mutation by pyrosequencing in fibrous dysplasia and other bone lesions. J Mol Diagn. 2011;13(2):137–42.Google Scholar
  41. 41.
    Eversole LR, Leider AS, Nelson K. Ossifying fibroma: a clinicopathologic study of sixty-four cases. Oral Surg Oral Med Oral Pathol. 1985;60(5):505–11.CrossRefPubMedGoogle Scholar
  42. 42.•
    El-Mofty SK. Fibro-osseous lesions of the craniofacial skeleton: an update. Head Neck Pathol. 2014;8(4):432–44. This manuscript represents the most recent updated review discussing the radio-clinical, histopathological and molecular features of benign fibro-osseous lesions of the craniofacial complex.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Commins DJ, Tolley NS, Milford CA. Fibrous dysplasia and ossifying fibroma of the paranasal sinuses. J Laryngol Otol. 1998;112(10):964–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Vlachou S, Terzakis G, Doundoulakis G, et al. Ossifying fibroma of the temporal bone. J Laryngol Otol. 2001;115(8):654–6.Google Scholar
  45. 45.
    MacDonald-Jankowski DS. Fibro-osseous lesions of the face and jaws. Clin Radiol. 2004;59(1):11–25.CrossRefPubMedGoogle Scholar
  46. 46.
    Sciubba JJ, Younai F. Ossifying fibroma of the mandible and maxilla: review of 18 cases. J Oral Pathol Med. 1989;18(6):315–21.CrossRefPubMedGoogle Scholar
  47. 47.
    Hamner JE, 3rd, PM Lightbody, Ketcham AS, et al. Cemento-ossifying fibroma of the maxilla. Oral Surg Oral Med Oral Pathol. 1968;26(4):579–87.Google Scholar
  48. 48.
    Waldron CA, Giansanti JS. Benign fibro-osseous lesions of the jaws: a clinical-radiologic-histologic review of sixty-five cases. II. Benign fibro-osseous lesions of periodontal ligament origin. Oral Surg Oral Med Oral Pathol. 1973;35(3):340–50.CrossRefPubMedGoogle Scholar
  49. 49.
    Zachariades N, Vairaktaris E, Papanicolaou S, et al. Ossifying fibroma of the jaws. Review of the literature and report of 16 cases. Int J Oral Surg. 1984;13(1):1–6.Google Scholar
  50. 50.
    Smith AG, Zavaleta A. Osteoma, ossifying fibroma, and fibrous dysplasia of facial and cranial bones. AMA Arch Pathol. 1952;54(6):507–27.PubMedGoogle Scholar
  51. 51.
    Sweet RM, Bryarly RC, Kornblut AD, et al. Recurrent cementifying fibroma of the jaws. Laryngoscope. 1981;91(7):1137–44.Google Scholar
  52. 52.
    Boysen ME, Olving JH, Vatne K, et al. Fibro-osseous lesions of the cranio-facial bones. J Laryngol Otol. 1979;93(8):793–807.Google Scholar
  53. 53.
    Dehner LP. Tumors of the mandible and maxilla in children. I. Clinicopathologic study of 46 histologically benign lesions. Cancer. 1973;31(2):364–84.Google Scholar
  54. 54.
    Slootweg PJ. Lesions of the jaws. Histopathology. 2009;54(4):401–18.CrossRefPubMedGoogle Scholar
  55. 55.
    Su L, Weathers DR, Waldron CA. Distinguishing features of focal cemento-osseous dysplasia and cemento-ossifying fibromas. II. A clinical and radiologic spectrum of 316 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(5):540–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Su L, Weathers DR, Waldron CA. Distinguishing features of focal cemento-osseous dysplasias and cemento-ossifying fibromas: I. A pathologic spectrum of 316 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(3):301–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Gollin SM, Storto PD, Malone PS, et al. Cytogenetic abnormalities in an ossifying fibroma from a patient with bilateral retinoblastoma. Genes Chromosomes Cancer. 1992;4(2):146–52.Google Scholar
  58. 58.
    Dal Cin P, Sciot R, Fossion E, et al. Chromosome abnormalities in cementifying fibroma. Cancer Genet Cytogenet. 1993;71(2):170–2.Google Scholar
  59. 59.
    Sawyer JR, Tryka AF, Bell JM, et al. Nonrandom chromosome breakpoints at Xq26 and 2q33 characterize cemento-ossifying fibromas of the orbit. Cancer. 1995;76(10):1853–9.Google Scholar
  60. 60.
    Pimenta FJ, Gontijo Silveira LF, Tavares GC, et al. HRPT2 gene alterations in ossifying fibroma of the jaws. Oral Oncol. 2006;42(7):735–9.Google Scholar
  61. 61.
    Zhang TH, Liu HC, Liao GQ, et al. Detection of Notch signaling molecules in cemento-ossifying fibroma of the jaws. J Oral Pathol Med. 2010;39(3):263–8.Google Scholar
  62. 62.
    Qin H, Qu C, Yamaza T, et al. Ossifying fibroma tumor stem cells are maintained by epigenetic regulation of a TSP1/TGF-beta/SMAD3 autocrine loop. Cell Stem Cell. 2013;13(5):577–89.Google Scholar
  63. 63.
    Patel MM, Wilkey JF, Abdelsayed R, et al. Analysis of GNAS mutations in cemento-ossifying fibromas and cemento-osseous dysplasias of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(5):739–43.Google Scholar
  64. 64.•
    Shi RR, Li XF, Zhang R, et al. GNAS mutational analysis in differentiating fibrous dysplasia and ossifying fibroma of the jaw. Mod Pathol. 2013;26:1023–31. This manuscript represents a large recent study confirming that mutational analysis of GNAS gene is a reliable adjunct to differentiate ossifying fibroma and fibrous dysplasia of the jaws.Google Scholar
  65. 65.•
    Dujardin F, Binh MB, Bouvier C, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol. 2011;24(5):624–37. This manuscript represents the first immunohistochemical and molecular study showing that MDM2 espression/amplification is a sensitive marker for the diagnosis of low-grade osteosarcomas.Google Scholar
  66. 66.
    El-Mofty S. Psammomatoid and trabecular juvenile ossifying fibroma of the craniofacial skeleton: two distinct clinicopathologic entities. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(3):296–304.CrossRefPubMedGoogle Scholar
  67. 67.
    Slootweg PJ, Muller H. Differential diagnosis of fibro-osseous jaw lesions. A histological investigation on 30 cases. J Craniomaxillofac Surg. 1990;18(5):210–4.CrossRefPubMedGoogle Scholar
  68. 68.
    Barnes L, Eveson JW, Reichart P, et al. World Health Organization Classification of Tumours. Pathology and genetics of head and neck tumours. 2005, Lyon: IARC Press. 430.Google Scholar
  69. 69.
    Sarode, SC, Sarode GS, Waknis P, et al. Juvenile psammomatoid ossifying fibroma: a review. Oral Oncol. 2011;47(12):1110–6.Google Scholar
  70. 70.
    Phattarataratip E, Pholjaroen C, Tiranon P. A clinicopathologic analysis of 207 cases of benign fibro-osseous lesions of the jaws. Int J Surg Pathol. 2014;22(4):326–33.CrossRefPubMedGoogle Scholar
  71. 71.
    Johnson LC, Yousefi M, Vinh TN, et al. Juvenile active ossifying fibroma. Its nature, dynamics and origin. Acta Otolaryngol Suppl. 1991;488:1–40.Google Scholar
  72. 72.
    Han J, Hu L, Zhang C, et al. Juvenile ossifying fibroma of the jaw: a retrospective study of 15 cases. Int J Oral Maxillofac Surg, 2016;45(3):368–76.Google Scholar
  73. 73.
    Makek MS. So called “fibro-osseous lesions” of tumorous origin. Biology confronts terminology. J Craniomaxillofac Surg. 1987;15(3):154–67.CrossRefPubMedGoogle Scholar
  74. 74.
    Makek M. Clinical pathology and differential diagnosis of fibro-osseous lesions of the maxillofacial area--new aspects. Dtsch Z Mund Kiefer Gesichtschir. 1986;10(3):212–7.PubMedGoogle Scholar
  75. 75.•
    Tabareau-Delalande F, Collin C, Gomez-Brouchet A, et al. Chromosome 12 long arm rearrangement covering MDM2 and RASAL1 is associated with aggressive craniofacial juvenile ossifying fibroma and extracranial psammomatoid fibro-osseous lesions. Mod Pathol. 2015;28(1):48–56. This manuscript reports the first recurrent molecular abnormality, with a potential prognostic significance, to be observed in juvenile ossifying fibroma.Google Scholar
  76. 76.
    Weaver J, Downs-Kelly E, Goldblum JR, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol. 2008;21(8):943–9.Google Scholar
  77. 77.
    Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31(10):1476–89.Google Scholar
  78. 78.
    Thariat, J, Julieron M, Brouchet A, et al. Osteosarcomas of the mandible: are they different from other tumor sites? Crit Rev Oncol Hematol. 2012;82(3):280–95.Google Scholar
  79. 79.•
    Thariat J, Schouman T, Brouchet A, et al. Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network. GETTEC/REFCOR and SFCE Ann Oncol. 2013;24(3):824–31. This manuscript represents the largest homogeneous series on multidisciplinary management of osteosarcoma of the mandible.Google Scholar
  80. 80.
    Liu XW, Zi Y, Xiang LB, et al, Periosteal osteosarcoma: a review of clinical evidence. Int J Clin Exp Med. 2015;8(1):37–44.Google Scholar
  81. 81.
    Yoshida A, Ushiku T, Motoi T, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010;23(9):1279–88.Google Scholar
  82. 82.
    Yoshida A, Ushiku T, Motoi T, et al. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol. 2012;36(3):423–31.Google Scholar

Copyright information

© Springer International Publishing AG 2016

Authors and Affiliations

  • Flore Tabareau-Delalande
    • 1
    • 2
  • Gonzague de Pinieux
    • 1
    • 3
    • 4
    Email author
  1. 1.University François RabelaisToursFrance
  2. 2.Department of PathologyCentre Hospitalier Régional d’OrléansOrleansFrance
  3. 3.Department of PathologyCentre Hospitalier Universitaire de ToursToursFrance
  4. 4.INSERM, UMR 957, Laboratory for Bone Resorption Physiopathology and Primary Bone Tumour Therapy, Faculty of MedicineUniversity of NantesNantesFrance

Personalised recommendations